Advanced Cyclotron Systems

What Advanced Cyclotron Systems does

Advanced Cyclotron Systems Inc. (ACSI), founded in 1989 and headquartered in Richmond, British Columbia, Canada, designs, manufactures, and services commercial cyclotron systems used to produce medical radioisotopes for nuclear medicine imaging. The company emerged from a technology transfer arrangement with TRIUMF, Canada's National Laboratory for Particle and Nuclear Physics, after parent affiliate EBCO Industries built a 500 MeV cyclotron there in 1979. ACSI operates within EBCO Industries' broader 60-year Canadian manufacturing footprint and is privately held.

ACSI's core platform is a four-model TR series of negative-ion cyclotrons — the TR-19 (PET-class, 12-19 MeV, up to 400 µA), TR-24 (12-25 MeV, up to 800 µA, upgradeable to 30 MeV), TR-FLEX (12-30 MeV, up to 800 µA in a 1.7m x 1.7m footprint), and TR-30 (15-33 MeV, up to 1,600 µA) — supported by an integrated targetry portfolio covering F-18, 68Ga, 11C, 15O water, gas, and solid targets, plus configurable beam lines and the High Current Solid Target Station. Differentiating design elements include an external ion source enabling filament replacement in minutes without breaking vacuum, real variable energy extraction (0.1 MeV precision) on each target port, oil-free cryo-pump vacuum systems, and modular shielding solutions. TR systems are designed for 30-year operational lifespans with on-site upgrade capability. ACSI also markets branded radioisotope products, CYCLOTEC (cyclotron-produced Tc-99m) and CYCLOMOLY (Mo-99), developed with Canadian academic and research partners.

The company sells directly to enterprise customers — commercial radiopharmaceutical producers, hospital-based nuclear medicine departments, research institutions, and government-led isotope supply networks — via a direct enterprise field-sales motion, quote-based capital equipment pricing, factory and on-site training included with purchase, and annual training workshops. Named customers include BWXT (Nordion), Curium, GE Healthcare, and Nihon Medi-physics in commercial radiopharmaceuticals, and TRIUMF and Helmholtz-Zentrum Dresden-Rossendorf in research. Revenue streams comprise initial cyclotron system sales (hardware), integrated targetry and beam line sales, ongoing service, maintenance, and on-site upgrades, and branded radioisotope supply. With no publicly disclosed revenue or funding, the company is positioned as a stable, privately-held niche capital-equipment OEM with long customer relationships and recurring aftermarket revenue.

Name

Advanced Cyclotron Systems

Legal name

Advanced Cyclotron Systems, Inc.

Website

https://advancedcyclotron.com

Company type

Private

Founded year

1989

Operating status

Operating

Headcount range

101–250 employees

Short description

Advanced Cyclotron Systems designs and manufactures commercial cyclotron systems (TR-19, TR-24, TR-FLEX, TR-30) for medical radioisotope production, serving radiopharmaceutical producers, hospital nuclear medicine departments, research institutions, and national isotope supply networks worldwide with related targetry, beam lines, and branded isotope products.

Ownership category

akta.pro rank

Product category

Particle Accelerator Systems (Medical Cyclotrons)

NAICS

Irradiation Apparatus Manufacturing (334517)

SIC

X-Ray Apparatus & Tubes & Related Irradiation Apparatus (3844)

akta.pro primary industry

Radioisotope Production (Reactor/Cyclotron/Gamma) (HLAIAGAD)

akta.pro secondary industries

Medical Radioisotope Production (Reactor/Cyclotron, Mo-99/Tc-99m, I-131, Lu-177, etc.) (EUAKAIAA), Nuclear Medicine Imaging Tracers & PET/SPECT Supply Chain (FDG, Ga-68, logistics/cold chain) (EUAKAIAE)

Keywords

• Cyclotron systems
• Medical radioisotope production
• Particle accelerator equipment
• Nuclear medicine equipment
• PET SPECT isotopes

Headquarters

HQ city

Richmond

HQ country

Canada

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Supply Chain, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

1. Cyclotron System Sales: Direct sale of cyclotron systems including TR-19, TR-24, TR-FLEX, and TR-30 models. Systems include initial installation and training. Major customers include BWXT (Nordion), Curium, GE Healthcare, and Nihon Medi-physics.
2. Service and Support: Ongoing service, maintenance, and technical support for cyclotron systems. Factory and on-site training included with purchase. Annual training workshops on cyclotron theory, design and operation.
3. Targetry and Beam Line Systems: Sale of liquid, gas, and solid targets along with beam line configurations and integrated radioisotope production systems.
4. Cyclotron Upgrade Services: On-site upgrade capabilities for existing cyclotron systems as technology advances. TR cyclotron systems are designed to operate for 30 years with ability to be upgraded on-site.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

Core offering

Advanced Cyclotron Systems Inc. (ACSI) designs, manufactures, and services commercial cyclotron systems used to produce medical radioisotopes for nuclear medicine imaging. Its product line spans four cyclotron models (TR-19, TR-24, TR-FLEX, TR-30) covering 12–33 MeV variable energy and beam currents up to 1600 µA, complemented by integrated targetry, beam-line systems, and proprietary radioisotope production technologies such as CYCLOTEC (cyclotron-produced Tc-99m) and CYCLOMOLY (Mo-99).

Product overview

Advanced Cyclotron Systems Inc. (ACSI) manufactures a portfolio of four cyclotron models (TR-19, TR-24, TR-FLEX, and TR-30) that represent the most technologically advanced commercial cyclotrons in the world. These cyclotron systems are designed for rapid, reliable, and high-yielding production of radioisotopes for nuclear medicine, particularly PET and SPECT imaging. The product line ranges from the compact TR-19 (12-19 MeV, up to 400 μA) for PET isotope production, through the versatile TR-24 (12-25 MeV, up to 800 μA) bridging PET and SPECT, to the high-performance TR-FLEX (12-30 MeV, up to 800 μA) combining PET cyclotron size with 30 MeV capacity, and the flagship TR-30 (15-33 MeV, up to 1600 μA) as the most powerful commercial cyclotron. Supporting the cyclotron core are comprehensive targetry solutions including F-18, 68Ga, 15O water, 11C targets, high current solid target stations, gas target stations, and beam line systems. ACSI also produces branded radioisotopes including CYCLOTEC™ (cyclotron-produced technetium-99m) and CYCLOMOLY™ (molybdenum-99). The systems are built for 24/7 production schedules with industry-leading uptime and include factory and on-site training with purchase.

Differentiator

Problem solved

Functional benefit

Products and services

• TR-19 Cyclotron High-performance PET cyclotron with real variable energy from 12 MeV to 19 MeV and beam current up to 400 µA. Features external ion source, cryo-pump oil-free vacuum, and local target shielding. Designed for hospital nuclear medicine departments and PET isotope production.
• TR-30 Cyclotron Flagship high-energy commercial cyclotron with variable energy from 15 MeV to 33 MeV and beam current up to 1600 µA. Built for 24/7 commercial production and supports up to 6 external beam lines for simultaneous production of multiple radioisotopes.
• TR-24 Cyclotron Medium-energy cyclotron bridging PET and SPECT isotope production with variable energy from 12 to 25 MeV and beam current up to 800 µA. Upgradeable to 30 MeV and holds the F-18 production record of 1700 GBq in 2 hours.
• TR-FLEX Cyclotron Compact, versatile 30 MeV-class cyclotron combining PET-cyclotron footprint with commercial 30 MeV energy and power. Variable energy from 12 to 30 MeV and beam current up to 800 µA. Most compact non-superconducting 30 MeV cyclotron ever built (1.7m x 1.7m, 24 tons).
• Targetry Systems Integrated targetry portfolio comprising F-18 targets (SMT, STT, LT volumes 1.8–3.8 mL), 68Ga targets, 11C targets (CO2 and CH4), 15O-water targets (26 mL), gas target stations for ultra-pure I-123 production, and the High Current Solid Target Station (HCSTS) capable of 500–600 µA beam currents.
• External Beam Line Systems External beam line configurations for TR-19 (vertical dipole, 2 branches), TR-24/TR-FLEX (1–6 lines, Y-shaped), and TR-30 (1–6 lines with three branches per side), including target selectors, single target ports, and integrated solid target stations.
• CYCLOTEC™ (Cyclotron-Produced Tc-99m) Proprietary cyclotron-produced technetium-99m production technique developed in collaboration with Canadian academic partners to enable domestic supply of this critical medical isotope.
• CYCLOMOLY™ (Cyclotron-Produced Mo-99) Proprietary molybdenum-99 production technique made on ACSI cyclotrons; can be used as a generator to produce CYCLOTEC (Tc-99m).
• Cyclotron Service, Training, and Upgrade Support Ongoing service, maintenance, factory and on-site training, annual training workshops on cyclotron theory, design and operation, and on-site upgrade services for existing cyclotron systems. Supports 30-year operational lifespan with on-site upgrade capability.

Quantifiable outcome

• TR-30 achieves >95% beam transmission from cyclotron center to extraction point
• +3 more outcomes

Named customers6 records

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Two partnerships are on record, tiered core and foundational.

• Canadian Academic Research Labs and UniversitiescoreStrategic or Co-development PartnerACSI collaborates with Canadian research labs and universities to develop cyclotron production techniques for medical isotopes. Together they established pilot facilities demonstrating high-scale cyclotron production of Tc-99m and created the national CYCLOTEC network for domestic technetium supply.
• TRIUMFfoundationalStrategic or Co-development PartnerTRIUMF (TRI-University Meson Facility), Canada's National Laboratory for Particle and Nuclear Physics, originated the cyclotron technology that ACSI commercialized. In 1979, EBCO (ACSI's predecessor) was contracted to help build a 500 MeV cyclotron at TRIUMF, leading to technology transfer and commercialization in 1989.

Scale indicators8 records

Recent moves6 records

Expansion highlights5 records

Market position

Competitive moat5 records

Key risks1 record

Key highlights7 records

Customer concentration

• Xx.com/acyclotron
• YouTubevimeo.com/70587552
• Facebookfacebook.com/advancedcyclotron
• LinkedInlinkedin.com/company/advanced-cyclotron-systems-inc-

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Advanced Cyclotron Systems